A common matrix metalloproteinase (MMP)-2 polymorphism affects plasma MMP-2 levels in subjects environmentally exposed to mercury

Belo, 2009, Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents, Clin Biochem, 42, 984, 10.1016/j.clinbiochem.2009.03.025 Belvisi, 2003, The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs?, Inflamm Res, 52, 95, 10.1007/s000110300020 Berglund, 2005, Inter-individual variations of human mercury exposure biomarkers: a cross-sectional assessment, Environ Health, 4, 20, 10.1186/1476-069X-4-20 Boffetta, 2001, Mortality from cardiovascular diseases and exposure to inorganic mercury, Occup Environ Med, 58, 461, 10.1136/oem.58.7.461 Bonnema, 2007, Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs), J Card Fail, 13, 530, 10.1016/j.cardfail.2007.04.010 Castro, 2008, Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats, Atherosclerosis, 198, 320, 10.1016/j.atherosclerosis.2007.10.011 Castro, 2009, Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension, Free Radic Biol Med, 46, 1298, 10.1016/j.freeradbiomed.2009.02.011 Castro, 2010, Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling, Matrix Biol, 29, 194, 10.1016/j.matbio.2009.11.005 Ceron, 2010, Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension, Br J Pharmacol, 160, 77, 10.1111/j.1476-5381.2010.00678.x Chow, 2007, Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature, Br J Pharmacol, 152, 189, 10.1038/sj.bjp.0707344 Clarkson, 2006, The toxicology of mercury and its chemical compounds, Crit Rev Toxicol, 36, 609, 10.1080/10408440600845619 de Marco, 2010, Environmental Exposure to Methylmercury is Associated with a Decrease in Nitric Oxide Production, Basic Clin Pharmacol Toxicol, 106, 411 Demacq, 2009, A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients, Pharmacogenomics J, 9, 265, 10.1038/tpj.2009.13 Gerlach, 2007, Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma, Clin Biochem, 40, 119, 10.1016/j.clinbiochem.2006.10.007 Gillian, 1997, Control of preanalytical variation in trace element determinations; approved guideline, National Committee for Clinical Laboratory Standards, 17, C-38A Goncalves, 2009, Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome, Clin Chim Acta, 403, 173, 10.1016/j.cca.2009.02.013 Goulle, 2005, Metal and metalloid multi-elementary ICP–MS validation in whole blood, plasma, urine and hair. Reference values, Forensic Sci Int, 153, 39, 10.1016/j.forsciint.2005.04.020 Guallar, 2002, Mercury, fish oils, and the risk of myocardial infarction, N Engl J Med, 347, 1747, 10.1056/NEJMoa020157 Hojo, 2001, Expression of matrix metalloproteinases in patients with acute myocardial infarction, Jpn Circ J, 65, 71, 10.1253/jcj.65.71 Jacob-Ferreira, 2009, Mercury exposure increases circulating net matrix metalloproteinase (MMP)-2 and MMP-9 activities, Basic Clin Pharmacol Toxicol, 105, 281, 10.1111/j.1742-7843.2009.00443.x Jacob-Ferreira, 2010, A functional matrix metalloproteinase (MMP)-9 polymorphism modifies plasma MMP-9 levels in subjects environmentally exposed to mercury, Sci Total Environ, 408, 4085, 10.1016/j.scitotenv.2010.05.036 Kai, 1998, Peripheral blood levels of matrix metalloproteases-2 and −9 are elevated in patients with acute coronary syndromes, J Am Coll Cardiol, 32, 368, 10.1016/S0735-1097(98)00250-2 Lacchini, 2010, Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients, Clin Chim Acta, 411, 1940, 10.1016/j.cca.2010.08.008 Martinez, 2008, Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats, Eur J Pharmacol, 591, 224, 10.1016/j.ejphar.2008.06.096 Martins-Oliveira, 2009, Different circulating metalloproteinases profiles in women with migraine with and without aura, Clin Chim Acta, 408, 60, 10.1016/j.cca.2009.07.008 Mergler, 2007, Methylmercury exposure and health effects in humans: a worldwide concern, Ambio, 36, 3, 10.1579/0044-7447(2007)36[3:MEAHEI]2.0.CO;2 Morimoto, 1997, Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases, and extracellular matrix mRNA following exposure to mineral fibers and cigarette smoke in vivo, Environ Health Perspect, 105, 1247, 10.1289/ehp.97105s51247 Ning, 2007, Cigarette smoke stimulates matrix metalloproteinase-2 activity via EGR-1 in human lung fibroblasts, Am J Respir Cell Mol Biol, 36, 480, 10.1165/rcmb.2006-0106OC Noji, 2004, Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction, Circ J, 68, 355, 10.1253/circj.68.355 Paczek, 2008, Trypsin, elastase, plasmin and MMP-9 activity in the serum during the human ageing process, Age Ageing, 37, 318, 10.1093/ageing/afn039 Palei, 2008, Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension, Clin Biochem, 41, 875, 10.1016/j.clinbiochem.2008.04.015 Palmer, 2006, Determination of lead, cadmium and mercury in blood for assessment of environmental exposure: a comparison between inductively coupled plasma–mass spectrometry and atomic absorption spectrometry, Spectrochim Acta Part B At Spectrosc, 61, 980, 10.1016/j.sab.2006.09.001 Passos, 2008, Daily mercury intake in fish-eating populations in the Brazilian Amazon, J Expo Sci Environ Epidemiol, 18, 76, 10.1038/sj.jes.7500599 Price, 2001, Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation, J Biol Chem, 276, 7549, 10.1074/jbc.M010242200 Ra, 2007, Control of matrix metalloproteinase catalytic activity, Matrix Biol, 26, 587, 10.1016/j.matbio.2007.07.001 Raitio, 2005, Levels of matrix metalloproteinase-2, −9 and −8 in the skin, serum and saliva of smokers and non-smokers, Arch Dermatol Res, 297, 242, 10.1007/s00403-005-0597-1 Rizzi, 2010, Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension, J Card Fail, 16, 599, 10.1016/j.cardfail.2010.02.005 Salonen, 2000, Mercury accumulation and accelerated progression of carotid atherosclerosis: a population-based prospective 4-year follow-up study in men in eastern Finland, Atherosclerosis, 148, 265, 10.1016/S0021-9150(99)00272-5 Segura-Valdez, 2000, Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD, Chest, 117, 684, 10.1378/chest.117.3.684 Souza-Costa, 2007, Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene, Atherosclerosis, 193, 438, 10.1016/j.atherosclerosis.2006.07.020 Van den Steen, 2002, Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9), Crit Rev Biochem Mol Biol, 37, 375, 10.1080/10409230290771546 Virtanen, 2005, Mercury, fish oils, and risk of acute coronary events and cardiovascular disease, coronary heart disease, and all-cause mortality in men in eastern Finland, Arterioscler Thromb Vasc Biol, 25, 228, 10.1161/01.ATV.0000150040.20950.61 Virtanen, 2007, Mercury as a risk factor for cardiovascular diseases, J Nutr Biochem, 18, 75, 10.1016/j.jnutbio.2006.05.001 Visse, 2003, Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry, Circ Res, 92, 827, 10.1161/01.RES.0000070112.80711.3D Woessner, 1998, The matrix metalloproteinase family, 1 Wright, 2007, Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-alpha signaling, Am J Physiol Lung Cell Mol Physiol, 292, L125, 10.1152/ajplung.00539.2005